NL-OMON26222
Recruiting
Not Applicable
A phase I Clinical Trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS).
Radboud University Nijmegen Medical Centre0 sites18 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myelodysplastic syndrome, Tipifarnib (ZARNESTRA), Bortezomib (VELCADE).
- Sponsor
- Radboud University Nijmegen Medical Centre
- Enrollment
- 18
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. MDS (including the non\-proliferative form of CMML, i.e. CMML with a WBC count \< 12,0 x 109\) /L with \< 30% blast cells in the bone marrow and with \< 5% circulating blasts);
- •2\. IPSS: Intermediate Risk\-2 or High Risk;
Exclusion Criteria
- •1\. IPSS: Low risk and Intermediate\-1 category;
- •2\. Candidates for allogeneic stem cell transplantation;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)myelodysplasiamyelodysplastic syndroom10018865NL-OMON30154niversitair Medisch Centrum Sint Radboud18
Recruiting
Phase 1
A Study of ICP-033 in Patients With Advanced Solid TumorsPatients With Advanced Solid TumorsNCT05367232Beijing InnoCare Pharma Tech Co., Ltd.60
Unknown
Phase 1
A Study of CSPCHA131 in Patients With Advanced Solid TumorAdvanced Solid TumorsNCT04325711CSPC ZhongQi Pharmaceutical Technology Co., Ltd.100
Completed
Phase 1
Mesenchymal Stem Cells Transplantation in newly diagnosed Type-1 Diabetes PatientsDiabetes.Insulin-dependent diabetes mellitusIRCT2016070428786N1Royan Institute20
Recruiting
Phase 1
A Phase 1 Study of BB102 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06258408Broadenbio Ltd., Co.78